c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors

Citation
Yt. Kim et al., c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors, CANCER LETT, 132(1-2), 1998, pp. 91-97
Citations number
34
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
CANCER LETTERS
ISSN journal
03043835 → ACNP
Volume
132
Issue
1-2
Year of publication
1998
Pages
91 - 97
Database
ISI
SICI code
0304-3835(19981023)132:1-2<91:COAIOC>2.0.ZU;2-D
Abstract
Overexpression of the c-erbB-2 oncoprotein has been detected in human adeno carcinoma of the breast, cervix and salivary gland, in all of which an asso ciation between the overexpression of the c-erbB-2 and a poor prognosis of the disease has been reported. However, the prognostic role of c-erbB-2 onc oprotein in ovarian carcinoma remains controversial. We measured c-erbB-2 o ncoprotein with an enzyme-linked immunosorbent assay (ELISA). Patients with invasive ovarian cancer were found to have significantly higher median c-e rbB-2 oncoprotein expression than patients with either benign ovarian cyst (P = 0.002) or control groups (P = 0.001), Overexpression of c-erbB-2 oncop rotein was found in seven (21.9%) of 32 epithelial ovarian cancers. Our res ults suggest that quantitative analysis of c-erbB-2 oncoprotein may be used to define the prognostic significance of ovarian carcinoma. (C) 1998 Elsev ier Science Ireland Ltd. All rights reserved.